Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antiba…
Biotechnology
US, Bridgewater [HQ]
Ratios
15 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| Gross Margin | 100.00 | 100.00 | 100.00 | - - | -157.77 | -191.61 | - - | - - | - - | 75.36 | 82.26 | 75.75 | 76.57 | 77.53 | 78.52 | |
| Profit Margin | 1,140.94 | -92.96 | -1,350.78 | - - | -487.59 | -688.34 | - - | - - | - - | -3,297.17 | -186.37 | -178.87 | -230.63 | -196.26 | -245.59 | |
| Operating Margin | -83.62 | -116.92 | -1,397.31 | - - | -478.39 | -759.70 | - - | - - | - - | -3,124.94 | -172.38 | -161.32 | -195.14 | -194.87 | -232.51 | |
|
EPS Growth
|
826.56 | -105.27 | -422.45 | 39.06 | -2.56 | -15.00 | -9.78 | -41.09 | -1.40 | -46.02 | 28.67 | - - | -28.90 | -0.77 | -36.57 | |
| EPS USD | 930.00 | -49.00 | -256.00 | -156.00 | -160.00 | -184.00 | -202.00 | -285.00 | -289.00 | -422.00 | -301.00 | -301.00 | -388.00 | -391.00 | -534.00 | |
| Return on Assets (ROA) | 93.41 | -3.28 | -42.67 | -26.94 | -31.77 | -34.29 | -33.15 | -74.08 | -41.69 | -53.64 | -34.26 | -36.94 | -34.95 | -29.07 | -56.37 | |
| Return on Equity (ROE) | 95.51 | -3.34 | -44.44 | -34.23 | -39.12 | -42.50 | -37.92 | -114.11 | -53.36 | -155.70 | -97.20 | -106.60 | -105.89 | -547.50 | 225.83 | |
| Return on Invested Capital (ROIC) | -6.96 | -4.24 | -52.57 | -30.81 | -33.03 | -36.57 | -34.31 | -82.90 | -45.28 | -58.60 | -35.82 | -39.15 | -35.81 | -37.88 | -81.65 | |
| Solvency | ||||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 0.16 | 0.08 | 0.86 | 12.63 | 11.15 | 10.77 | 7.05 | 23.03 | 12.03 | 52.36 | 53.49 | 50.85 | 49.24 | 71.11 | 90.54 | |
| Debt/Equity | 0.17 | 0.09 | 0.90 | 16.04 | 13.74 | 13.35 | 8.07 | 35.47 | 15.39 | 152.00 | 151.73 | 146.74 | 149.16 | 1,339.23 | -362.73 | |
| Debt/EBITDA | 157.30 | 131.61 | 38.56 | 170.49 | 173.28 | 154.05 | 219.30 | 62.21 | 172.62 | 58.44 | 39.17 | 49.23 | 27.99 | -22.66 | -107.08 | |
|
Debt/Capitalization
|
0.17 | 0.08 | 0.89 | 13.82 | 12.08 | 11.77 | 7.46 | 26.18 | 13.34 | 60.32 | 60.27 | 59.47 | 59.87 | 93.05 | 138.06 | |
| Long-Term Debt/Capitalization | - - | 0.04 | 0.80 | 11.87 | 10.23 | 11.77 | 6.60 | 26.18 | 13.34 | 60.32 | 59.52 | 58.71 | 59.46 | 93.01 | 138.53 | |
| Interest Debt per Share USD | 0.08 | 0.02 | 0.05 | 0.76 | 0.63 | 0.63 | 0.48 | 0.94 | 0.92 | 4.45 | 5.02 | 4.45 | 5.82 | 9.79 | 9.12 | |
| Debt Growth | -90.11 | -21.15 | 633.54 | 1,511.64 | 1.53 | 26.27 | 1.14 | 117.94 | 1.42 | 469.69 | 25.42 | 1.97 | 51.24 | 92.38 | 2.22 | |
| Liquidity | ||||||||||||||||
| Current Ratio | 4,480.69 | 3,258.37 | 1,728.81 | 594.26 | 705.90 | 839.09 | 1,294.39 | 601.69 | 872.10 | 650.86 | 651.33 | 524.29 | 619.27 | 669.35 | 411.77 | |
| Quick Ratio | 4,474.97 | 3,250.07 | 1,720.55 | 590.18 | 692.11 | 811.14 | 1,270.84 | 580.91 | 853.56 | 627.84 | 594.39 | 462.36 | 548.31 | 619.20 | 364.15 | |
| Cash Ratio | 458.11 | 321.74 | 331.65 | 576.50 | 692.11 | 811.14 | 1,270.84 | 580.91 | 853.56 | 620.92 | 571.83 | 448.42 | 530.30 | 564.56 | 213.79 | |
| Operating Cash Flow Ratio | -300 | -200 | -600 | -100 | -200 | -300 | -400 | -500 | -300 | -300 | -200 | -100 | -200 | -200 | -200 | |
| Turnover | ||||||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | 34.46 | 85.52 | 80.40 | 65.89 | 78.84 | 78.77 | |
| Receivables Turnover | 457.36 | 1,469.43 | 583.49 | - - | - - | - - | - - | - - | - - | 178.33 | 709.58 | 992.71 | 773.94 | 825.76 | 740.99 | |
| Payables Turnover | - - | - - | - - | 302.68 | 499.98 | 362.58 | 26.54 | 23.36 | 19.77 | 13.66 | 183.65 | 93.04 | 123.39 | 109.25 | 100.28 | |
|
Asset Turnover
|
8.19 | 3.53 | 3.16 | - - | 6.52 | 4.98 | - - | - - | - - | 1.63 | 18.38 | 20.65 | 15.16 | 14.81 | 22.95 | |
| Fixed Turnover | - - | 628.04 | 228.03 | - - | 634.66 | 152.64 | - - | - - | - - | 43.45 | 120.65 | 169.09 | 197.31 | 240.35 | 292.38 | |
| Coverage | ||||||||||||||||
| Interest Coverage | -1,110.63 | -7,423.85 | -617,190.00 | -5,561.99 | -2,280.89 | -3,617.60 | -4,066.91 | -4,957.12 | -3,188.52 | -1,206.57 | -849.11 | -897.15 | -908.66 | -1,807.92 | -930.58 | |
| Asset Coverage | 59,600 | 117,600 | 6,400 | 400 | 500 | 600 | 1,100 | 200 | 600 | 100 | 100 | 100 | 100 | 100 | - - | |
| Cash Flow Coverage (CFGR) | -5,294.23 | -4,708.54 | -2,510.81 | -159.95 | -237.05 | -259.16 | -400.56 | -267.76 | -287.25 | -81.49 | -63.13 | -54.18 | -59.34 | -34.00 | -44.54 | |
| EBITDA Coverage | -1,000 | -7,300 | -353,800 | -5,400 | -2,200 | -3,600 | -4,000 | -4,900 | -3,100 | -1,100 | -800 | -800 | -900 | -1,700 | -800 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | 120.92 | -7.70 | -83.78 | -23.32 | -9.43 | -11.89 | -11.13 | -21.54 | -9.28 | -32.17 | -12.60 | -9.05 | -14.23 | -19.59 | -17.22 | |
|
Price/Earnings (P/E)
|
82.70 | -1,299.05 | -119.35 | -428.85 | -1,060.51 | -840.76 | -898.51 | -464.21 | -1,077.52 | -310.90 | -793.94 | -1,104.86 | -702.61 | -510.50 | -580.60 | |
| Price/Earnings Growth (PEG) | -0.10 | 12.34 | -0.28 | 10.98 | -413.60 | -56.05 | -91.85 | -11.30 | -767.74 | -6.76 | 27.69 | - - | -24.31 | -660.25 | -15.88 | |
|
Price/Book (P/B)
|
78.99 | 43.34 | 53.04 | 146.78 | 414.91 | 357.36 | 340.68 | 529.69 | 574.93 | 484.08 | 771.68 | 1,177.77 | 744.01 | 2,795.01 | -1,311.15 | |
| Price/Tangible Book (P/TB) | 78.99 | 43.34 | 53.04 | 146.78 | 414.91 | 357.36 | 340.68 | 529.69 | 574.93 | 484.08 | 771.68 | 1,177.77 | 744.01 | 2,795.01 | -1,311.15 | |
| Price/Sales (P/S) | 943.59 | 1,207.64 | 1,612.21 | - - | 5,170.96 | 5,787.29 | - - | - - | - - | 10,250.93 | 1,479.69 | 1,976.29 | 1,620.44 | 1,001.90 | 1,425.92 | |
|
Price/Cash Flow (P/CF)
|
-888.84 | -1,082.38 | -235.76 | -572.14 | -1,274.34 | -1,033.19 | -1,054.51 | -557.76 | -1,300.51 | -390.80 | -805.63 | -1,481.33 | -840.60 | -613.89 | -811.57 | |
| Price/Free CF (P/FCF) | -888.84 | -8,451.06 | -228.36 | -566.84 | -1,252.18 | -953.94 | -1,019.54 | -542.24 | -1,276.51 | -369.58 | -689.37 | -1,436.65 | -824.06 | -599.11 | -791.95 | |
| Price/Operating CF (P/OCF) | -888.84 | -1,082.38 | -235.76 | -572.14 | -1,274.34 | -1,033.19 | -1,054.51 | -557.76 | -1,300.51 | -390.80 | -805.63 | -1,481.33 | -840.60 | -613.89 | -811.57 |